These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5822623)

  • 21. Irreversible enzyme inhibitors. 168. Irreversible inhibition of dihydrofolate reductase and cell wall transport by pyrimidines and dihydro-s-triazines with pyridinium side chains.
    Baker BR; Vermeulen NM; Ryan AJ
    J Med Chem; 1970 Mar; 13(2):280-4. PubMed ID: 5418502
    [No Abstract]   [Full Text] [Related]  

  • 22. Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
    Baker BR; Lourens GJ; Meyer RB; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):67-73. PubMed ID: 5763043
    [No Abstract]   [Full Text] [Related]  

  • 23. Irreversible enzyme inhibitors. CXLI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[p-(p-fluorosulfonylphenylureidomethyl)phenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):101-4. PubMed ID: 5763002
    [No Abstract]   [Full Text] [Related]  

  • 24. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
    Baker BR
    J Med Chem; 1968 May; 11(3):483-6. PubMed ID: 5241406
    [No Abstract]   [Full Text] [Related]  

  • 26. Irreversible enzyme inhibitors. CXXXIX. p-(4,6-Diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. VI. Further studies on effects of substitution on the propionamide bridge on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):92-4. PubMed ID: 5763049
    [No Abstract]   [Full Text] [Related]  

  • 27. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irreversible enzyme inhibitors. CX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. IV.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):34-7. PubMed ID: 5237172
    [No Abstract]   [Full Text] [Related]  

  • 31. Irreversible enzyme inhibitors. CLXXV. Irreversible inhibition of purified dihydrofolic reductase.
    Baker BR; Vermeulen NM
    J Med Chem; 1970 Nov; 13(6):1143-8. PubMed ID: 5479854
    [No Abstract]   [Full Text] [Related]  

  • 32. Irreversible enzyme inhibitors. CIX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. 3.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):26-33. PubMed ID: 5237171
    [No Abstract]   [Full Text] [Related]  

  • 33. Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):38-41. PubMed ID: 5237173
    [No Abstract]   [Full Text] [Related]  

  • 34. Irreversible enzyme inhibitors. CV. Differential irreversible inhibition of vertebrate dihydrofolic reductases by derivatives of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazines substituted with a terminal sulfonyl fluoride.
    Baker BR; Lourens GJ
    J Med Chem; 1967 Nov; 10(6):1113-22. PubMed ID: 6056040
    [No Abstract]   [Full Text] [Related]  

  • 35. Irreversible enzyme inhibitors. CLV. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[4-(omega-aminoalkoxy)-3-chlorophenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazines bearing a terminal sulfonyl fluoride.
    Baker BR; Janson EE
    J Med Chem; 1969 Jul; 12(4):672-6. PubMed ID: 5793160
    [No Abstract]   [Full Text] [Related]  

  • 36. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irreversible enzyme inhibitors. 198. Diaminodihydro-S-triazines and diaminopyrimidines bearing substituted (ureidomethyl)phenyl substituents as reversible inhibitors of dihydrofolate reductase.
    Ashton WT; Kirk LL; Baker BR
    J Med Chem; 1973 May; 16(5):453-6. PubMed ID: 4736964
    [No Abstract]   [Full Text] [Related]  

  • 38. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Mavandadi F; Queener SF
    J Med Chem; 1997 Mar; 40(7):1173-7. PubMed ID: 9089339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.